Page 22 - Numinus Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MindMed Will Use the Proceeds of the Offering for Investment in its Digital Medicine Division, for Further Investments in its Project Lucy and Project Layla, for its LSD Micro-Dosing ADHD Trials and for General Working Capital Purposes MindMed (OTCQB:MMEDF) announced that further to its previously announced offering on December 14 and December 15, 2020, it has filed a preliminary short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement among the company, the underwriters Canaccord Genui...

This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to request unapproved drugs for patients with serious or life-threatening conditions if other therapies have failed, aren’t suitable or are not available in Canada. The proposal includes bringing MDMA and psilocybin back from a 2013 amendment to the Food and Drug Regulations that restricted these drugs, among others, to be part of the SAP. If the once restricted drugs qualify again for t...

), which this week acquired Adelia Therapeutics, a transformational move that broadened addressable indications in its pipeline and strengthened its scientific team. Cybin has a three-pillar approach,  its initial sights set on treating major depression disorder (MDD) now expanded to address additional indication as well through innovative psychedelic therapeutics development and unique delivery technologies. Cybin stands shoulder-to-shoulder with peers striving for a world of better mental well-being such as COMPASS Pathways Plc (NASDAQ:CMPS), Mind Medicine Inc (OTC:MMEDF) (NEO: MMED), N...

Healthcare professionals okayed to use magic mushrooms for training in psilocybin therapy Psychologists, psychiatrists, social workers, and nurses are among 17 healthcare professionals granted the exemption by Health Canada this week by Enzo DiMatteo on December 12th, 2020 at 11:00 PM 1 of 1 2 of 1 The use of psychedelics in therapy hit another high this week. A group of 17 healthcare professionals, among them psychologists, psychiatrists, social workers, and nurses, became the first in Canada to be granted a legal exemption to use psilocybin—the active ingredient in what are known a...

Share:   First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in need before formal drug approval  VANCOUVER, BC, Dec. 11, 2020 /CNW/ - .  ("Numinus" or the "Company") (TSXV:NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, commends Health Canada's leadership for its intention to revise the Special Access Programme (SAP) to permit access to MDMA and psilocybin-assisted psychotherapy. The intended SAP revision, anno...